Blog Archive

RECENT FACET SUCCESSES – JUST A FEW HIGHLIGHTS FACET HELPS GOVERNMENT INVESTIGATE DEA DRUG OF CONCERN: Facet champions IND preparation and submission to study PK and safety of widely available supplement.  A large ex-US C...

FACET BY THE NUMBERS Total submissions to FDA April – June 2023:  35 (on average almost 3 submissions a week!) Early-stage development highlights: preparation/submission of 3 new INDs and submitted over 22 IND amendments (e.g.,...

FDA ROUNDUP: FDA issues important draft guidance for developers of psychedelic drugs for potential treatment of medical conditions (June 23, 2023).  Currently, there are hundreds of organizations across the world who are develo...

DID YOU KNOW? Facet helps to develop products in every therapeutic area and has specialty expertise in ophthalmology, oncology, diagnostic/therapeutic radiopharmaceuticals, and controlled substances Facet’s scientific experts ...

Team FocusDr. Jason Mercer attended the annual Food and Drug Law Institute (FDLI) annual conference May 17-18 in Washington, DC.  The FDLI annual conference addresses complex legal, regulatory, compliance, and policy issues fac...

RECENT FACET SUCCESSES – JUST A FEW HIGHLIGHTS ULTRA RARE DISEASE DEVELOPMENT: Facet helps growing start-up design a development plan for a pediatric ultra rare disease indication. A small ex-US company asked Facet to pro...

RECENT FACET SUCCESSES – JUST A FEW HIGHLIGHTSULTRA RARE DISEASE DEVELOPMENT: Facet helps growing start-up design a development plan for a pediatric ultra rare disease indication. A small ex-US company asked Facet to provide US...

FACET BY THE NUMBERS Total submissions to FDA January – March 2023:  41 (on average over 3 submissions a week!)  Early-stage development highlights:  preparation/submission of 7 new INDs and submitted over 20 IND amendments (e....